Clinical trialNCT06118086RecruitingPhase 1/PHASE2Interventional

Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

SponsorRemix TherapeuticsEnrollment125Adenoid Cystic CarcinomaMetastatic Adenoid Cystic CarcinomaRecurrent Adenoid Cystic Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Mythili Koneru, MD, PhD
Remix Therapeutics
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

France

Centre Antoine Lacassagne
Nice, France
Esma Saada-Bouzid, MD
Recruiting
Institut de Cancerologie Gustave-Roussy
Villejuif, France
Caroline Even, MD
Recruiting

United States

University of California San Francisco Helen Diller Comprehensive Cancer Center
San Francisco, California, United States
Alain Algazi, MD
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Guilherme Rabinowits, MD
Recruiting
Dana Farber Cancer Research Institute
Boston, Massachusetts, United States
Glenn Hanna, MD
Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
Paul L Swiecicki, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Alan L Ho, MD, PhD
Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Meredith McKean, MD
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Renata Ferrarotto, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

REM-422

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 20 Dec 2023
Primary completion: 30 Sept 2027
Completion: 30 Sept 2027
Last update posted: 24 Jun 2026
Registered enrollment: 125
Registry id: NCT06118086

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.